165  SC83288 is a clinical development candidate for the treatment of severe malaria.

164  Hand-powered ultralow-cost paper centrifuge.

163  Complete attenuation of genetically engineered Plasmodium falciparum sporozoites in human subjects.

162  The genome of Onchocerca volvulus, agent of river blindness.

161  Oral, ultra–long-lasting drug delivery: Application toward malaria elimination goals.

160  Tilting the balance between RNA interference and replication eradicates Leishmania RNA virus 1 and mitigates the inflammatory response.

159  The effect of mass mosquito trapping on malaria transmission and disease burden (SolarMal).

158  Comparative genomics reveals adaptive evolution of Asian tapeworm in switching to a new intermediate host.

157  Efficacy of the Olyset Duo net against insecticide-resistant mosquito vectors of malaria.

156  A selective inhibitor of the kinetoplastid proteasome (GNF6702) is identified that is highly efficacious in vivo, clearing the parasites that cause leishmaniasis, Chagas disease and sleeping sickness from mice, highlighting the possibility of developing a single class of drugs for these neglected diseases.

Free Images for Presentation: sunipix SUNIPIX